相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The ASAS Health Index: A New Era for Health Impact Assessment in Spondyloarthritis
Sara Alonso et al.
JOURNAL OF RHEUMATOLOGY (2022)
2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis
Daniel Wendling et al.
JOINT BONE SPINE (2022)
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
Robert B. M. Landewe et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Three-year cost-effectiveness analysis of the DRESS study: protocolised tapering is key
Nathan den Broeder et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
2018 APLAR axial spondyloarthritis treatment recommendations
Lai Shan Tam et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2019)
Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)
Line Uhrenholt et al.
BMJ OPEN (2019)
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Michael M. Ward et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity
Lise M. Verhoef et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2019)
Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis
Jordi Gratacos et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China
Kun-Peng Li et al.
ARCHIVES OF MEDICAL SCIENCE (2019)
Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study
Mireia Moreno et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Analysis of relapse rates and risk factors of tapering or stopping pharmacologic therapies in axial spondyloarthritis patients with sustained remission
Xiaochan Chen et al.
CLINICAL RHEUMATOLOGY (2018)
Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study
Robert Landewe et al.
LANCET (2018)
An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity Results From a Pragmatic Open-Label Trial
An Tran-Duy et al.
ARTHRITIS & RHEUMATOLOGY (2018)
An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS
Anna Molto et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Dosing down with biologic therapies: a systematic review and clinicians' perspective
Christopher J. Edwards et al.
RHEUMATOLOGY (2017)
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
Desiree van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis
Alexandre Sepriano et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review
Victoria Navarro-Compan et al.
RHEUMATOLOGY (2016)
Drug levels, immunogenicity and assessment of active sacroiliitis in patients with axial spondyloarthritis under biologic tapering strategy
Miriam Almirall et al.
RHEUMATOLOGY INTERNATIONAL (2016)
A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study
Jakub Zavada et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Evaluation of Health Outcomes with Etanercept Treatment in Patients with Early Nonradiographic Axial Spondyloarthritis
Maxime Dougados et al.
JOURNAL OF RHEUMATOLOGY (2015)
Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity
Chamaida Plasencia et al.
JOURNAL OF RHEUMATOLOGY (2015)
Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): study protocol for a randomized controlled trial
Caridad Pontes et al.
TRIALS (2015)
Infliximab Dose Reduction Sustains the Clinical Treatment Effect in Active HLAB27 Positive Ankylosing Spondylitis: A Two-Year Pilot Study
Boel Morck et al.
MEDIATORS OF INFLAMMATION (2013)
How Important is Early Therapy in Axial Spondyloarthritis?
Joachim Sieper et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2012)
The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general
M. Rudwaleit et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Anti-TNFα discontinuation in rheumatoid and psoriatic arthritis: Is it possible after disease remission?
Maria Sole Chimenti et al.
AUTOIMMUNITY REVIEWS (2011)
Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease
Victoria Navarro-Compan et al.
CLINICAL RHEUMATOLOGY (2011)
Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis
Jaejoon Lee et al.
CLINICAL RHEUMATOLOGY (2010)
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection
M. Rudwaleit et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
IMAGING PROGRESSION DESPITE CLINICAL REMISSION IN EARLY RHEUMATOID ARTHRITIS PATIENTS AFTER ETANERCEPT INTERRUPTION
B. Lagana et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
Etanercept 25 mg/week is effective enough remission for ankylosing spondylitis among to maintain Korean patients
Sang-Hoon Lee et al.
CLINICAL RHEUMATOLOGY (2008)
分享论文
